Cambridge Cognition Share Discussion Threads

[40 fathoms] 26/4/2022 11:58

The section below is taken from a recent article in the Guardian.



The super interesting bit is Monument have "developed a biomarker that it claims can predict POCD with 90% accuracy"

It is worth remembering that we own 30% of Monument after the spin out and we will get a gross royalty on commercialisation of its products. Monument also has a another drug under development targeting cognitive effects in Schizophrenia again with an associtated digital biomarker.

"Monument Therapeutics has reformulated a generic anti-inflammatory drug so that it can access the brain and potentially dampen down some of the brain inflammation that may be occurring post-surgery. It is preparing to launch a trial, initially in healthy volunteers, and if that proves successful, it will look to target POCD patients in the coming years.

But scientists are also searching for ways of pinpointing the patients most at-risk of developing POCD so that they can be specifically targeted with some of these interventions. Studies in cardiac patients have found that people with low levels of antibodies against bacterial endotoxins are particularly at risk of POCD, suggesting that infection could also play a role in these symptoms. Monument Therapeutics has also identified a biomarker that it claims can predict POCD with 90% accuracy.

“In future, we want to be able to measure people’s cognitive function before they go in for surgery, to get a measure of how vulnerable or resilient their brain is, and if they’re vulnerable, have a way to treat that,” says Barnett."

[40 fathoms] 14/4/2022 03:19

Here are the various links to the post results interviews on different platforms

Directors Talk



Proactive Investors



Vox Markets

[mdchand] 13/4/2022 09:41

Not sure if this is a pay wall article but IC are very positive on COG and its long term growth potential supported by a very high IP wall which makes it the market leader in this growing area.

[pre] 12/4/2022 14:03

Courtesy of Erratum posted on LSE thread - type http instead of HTpp and page 51 makes very interesting reading re: apple & Iphones etc:


erratum

Posts: 36

Price: 158.00

No Opinion

Apple/ Biogen Intuition StudyToday 14:46
It does not seem to have been posted on this board before but this Apple/Biogen study contract, that they won last year is hugely important and all investors and potential investors should be aware of it. I assume COG are unable to talk about it due to confidentiality constraints.

Cambridge Cognition is providing the cognitive tests to the Apple/Biogen sponsored Intuition Study. This is a huge and ground breaking digital study using IPhones and Apple watches to monitor @25,000 participants over a number of years and looking for signs of Mild Cognitive Impairment (MCI). It would seem that this contracts relates to the GBP2.3 million study win that they disclosed last year.

How do I know this ? Below is a link to a recent Biogen presentation and on page 51 you will see a reference to CANTAB being used as part of the Intuition study. For those that don't know CANTAB is COG's cognitive testing product. You can look up the Intuition study to see its purpose and scope, it is co-sponsored by Apple and Biogen



This is huge and completely ground breaking in and of itself but if the study produces useful insights who do you think Apple will call if they want to embed cognitive tests in to their products.

[40 fathoms] 12/4/2022 11:38

Brief results update.

[40 fathoms] 12/4/2022 10:02

I think the share price dip is a combination of things. Firstly we have come up pretty hard in last couple of weeks, secondly the market has been a bit skittish the last few days and I think if you don't know the company well it would be easy to see the company as expensive.

Give it a day or two as management gets out and about and talks about the structural outlook and specifically the outlook for COG. I imagine our new broker will be putting them in front of a new client base.

Also, I have just seen that Singer has taken up, marginally, its target price but taken down its recommendation from buy to hold. I think Mr Like's forecasts for next year are clearly wrong he has revenue only growing by 20% which will be off by at least half by my reckoning. Nevertheless maybe that also had a short term impact.

[igbertsponk] 12/4/2022 08:57

They seem well placed, enough cash to finance expansion without needing any more placings.

[mobtheplod] 12/4/2022 07:54

Hmmmm, do you think this is a case of sell on the news?

[purplepelmets] 12/4/2022 06:59

Margin will not stay the same, it will increase exponentially as revenue increases. That is the nature of software companies such as COG. We will be a very profitable little company in the not too distant future.

[40 fathoms] 12/4/2022 06:51

If history is any guide, in addition to the @7.5 million of backlog they anticipate to recognize during FY2022 they should be able to do at least @6 - 7 million in revenue won and recognized in the period. So we should be looking at revenue of at least 13 million and 14 million for FY22 at a minimum.

If margin stay they same and at 180p that should put us on a 2022 P/E of @40x with very significant growth still to come in the FY 2023 & 2024 as well. That is before any good news that may come from the Monument spin out.

[40 fathoms] 12/4/2022 06:19

Results are fantastic.

Profit of 0.5 million well ahead of forecast. Lots of cash, record revenue backlog, high visibility for FY22, confirmation of strategic tail winds, new (evolved) strategic plan and strong outlook.

[40 fathoms] 02/4/2022 04:03

When I checked 10 days ago there were 12 open positions most of them new roles and not replacements.

Today when I checked there are 18 open positions.

[mike24] 01/4/2022 09:06

get checked out now, mri scan, memantine not a cure for dementia,
but those coming off this medication can go into a
irriversible decline in months, as long covid cases will prove

SUN/TIMES 13th march 22
national/stats say 2.2 % suffer long covid = 1.5ml people
a hit of .04% with LC would cost the economy £10billion X five £50 bl
many of these with LC are high flyers
people at peak of physical fitness, 50% sufferers under 49yrs of age
THERE ARE MANY PARALLELS between L/C & ME & CFS

L/C sufferer of 2yrs is MP Andrew Gwynne (CFS) said we need the government to take this
issue seriously, see forums how to cope with me / cfs but no real cure as yet
no exercise whatsoever & rest, to cope with chronic fatigue syndrome
dementia /heart conditions should be approved exercises
5-11yr olds from 2/4/22 diluted jab available, to little to late

Daily Mail 25/11/2019 my eighty days of hell, by Conner Reed 25yrs,old, teaching in Wuhan
one of the first victims of long covid, as Kent Taylor sadly passed away,
in the article there were just 5 reported c/cases in the whole of London, as of last w/end
4.9million in uk with covid, what went wrong ?

the elderly most of whom were safe, hibernating could have been jabbed last
putting us to the back of the queue would have meant a few wks delay
now the drop in interest to keep vaccinations going will treble l/covid patients

Shane Warne 52yrs he'd caught covid twice, briefly put on a special ventilator as
part of a trial into long covid, did that contribute to his fatal heart attack?

David Brown has created app TMinus to cope with severe tinnitus estimated to
affect 1 in 15 people (source BBC news)

Times 14/5 a deeply embedded prejudice about the disease (me cfs) a chronic complex
medical condition, the disbelief,apathy and stigma of the medical profession (NHS)
and wider society, Maeve O'neil RIP (250000 affected in uk)

need to push the jabs to combat AF plus research into 1.5m global deaths from Aspergillus Fumigatus
causing biggest problem in NHS for those in intensive care = causing highest death rate

wk-end press 21 may, diabetes in middle age raises dementia risk, ONS says 1.7ml in uk
still suffering symptoms that started with c/19, 350,000 have left workforce due to pandemic

21JULY22 Team from London Uni, College, saying positive psychological factors can help reduce
dementia, what is not mentioned is the reverse can happen that tempory negative psychological factors
might cause a severe loss, brought on mainly by flu/colds etc, which gives a patient a wake up call
on what the depth of a loss can be like, despite a recovery usually in a couple of weeks

numbers living with dementia in UK set to rise to 1.6mil by 2040

(aug) doc's round uk at last coming to conclusion c19 triggers a variety of illnesses in a very
short time span, poss days /wks, plus a nasty dose of ordinary flu about, which c19 jab not effective
a big spike in health problems on those flying anywhere (the med the worst)

at last NICE are treating L/C as a complex multi-system illness affecting 10% of those who have had C19
22/9/22
top dementia consultant has added his weight to the theory of London U C, adding this counts
as a benefit of 75% with positive psychological factors and just 25% medication

[johnwise] 28/3/2022 06:26

28/03/2022 7:00am

RNS Number : 1491G

Cambridge Cognition Holdings PLC GBP1 million contract for pivotal autoimmune trial

[40 fathoms] 28/3/2022 06:13

There we go, another GBP 1 million contract

" Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a contract worth just over £1 million with a top 10 pharmaceutical company to provide digital cognitive assessments for a pivotal phase III autoimmune disease trial. Revenue from the contract is expected over the next three years."

[40 fathoms] 27/3/2022 00:14

Cambridge Cognition tipped in today’s Sunday Times


Behind pay wall but conclusion is

“ The pharmaceutical sector values Cambridge Cognition highly but the City doesn’t look to have realised how much. It is benefiting from an increase in the number of clinical trials and more drugs in the pipeline at pre-clinical stage.

Singer Capital Markets predicts sales will rise 24 per cent by next year. The stock should surge, too — buy.”

[40 fathoms] 24/3/2022 10:44

Plenty going on :

Firstly, Today we have change of NOMAD and broker.

Secondly, we have 12 open positions and most if not all of them are new hires and not replacements



Thirdly, we have recently outsourced a lot of our software development grunt work to South Africa.



Finally, plenty of progress being made at Monument Therapeutics ( as a reminder we hold an @ 35% equity stake and will receive significant royalties if successfully commercialised)

[sev22] 21/3/2022 08:15

According to Stockopedia COG are releasing their Full Year 2021 Earnings on Wednesday 23rd March 2022.

[40 fathoms] 08/3/2022 04:32

MB, I am not aware of this test but will certainly take a look. I think the biomarker diagnostic market is going to be very interesting and as I am sure you are aware there are a number of approaches and tests working their way towards the market. Any of these approaches would seem preferable to a lumber puncture, in my opinion.

[manuelbeanster] 08/3/2022 00:33

Thank you 40! You're always very knowledgeable and wise :)
By the way, have you heard about Synaps Dx and its test Discern? I came across it while studying Semler Scientific (also an interesting Medtech software company). Semler invested in Synaps recently, but sales have yet to ramp up. From what they advertise, Discern can identify early-stage AD with 95% certainty and distinguish it from other dementias. It's not software, you need to send a 3mm skin sample to their lab, but if it does what it promises, it's quite interesting.

[40 fathoms] 07/3/2022 11:58

In CNS for remote digital measures of cognition there is effectively no competition to Cogstate and Cambridge Cognition, for all the reasons we have mentioned before. To the extent that they do have competition it is pencil and paper tests.

Outside of CNS, I think you should be looking at it the other way around. To what extent should other CROs be worried about the competition to their offering. These guys don't have validated digital measures and it is much easier and cheaper for them to bring in a Cogstate or a Cambridge Cognition for that function. This is already happening Cogstate has partnered with ERT (Now Clario), Cambridge Cognition provides its services to a number of CROs.

As trials move more and more in to voice, wearables, RW etc these guys move further and further ahead, their tests get more and more sensitive. Pushing a pen and paper test on line with a rater looking over your shoulder on zoom is not competition. That said, I am not sure either Cogstate or Cambridge Cognition are interested in commodity style work. Both have excellent gross margins and a tonne of high margin growth ahead of them. One of the things Matthew Stork has done here to recognise what COG does is valuable to its clients and to make sure they are properly paid for work they do. We have 80% gross margins, from memory Cogstate has 60% so their is no need to chase after the crumbs. The difference in gross margins between the two before you ask, is we in essence just provide software, in addition to software Cogstate also provides services such as Raters and rater training and these are lower margin products. You will note the CGSs margin jumps about a bit based on the product mix booked during any reporting period.

[manuelbeanster] 06/3/2022 22:43

Hi guys,

Brad O'Connor, Cogstate's CEO, recently mentioned that he calculates Cogstate market share in all Alzheimer's Disease-related clinical trials in the US to be 13%.

When asked about who he believed he was going up against, he mentioned Signant Health and WCG (VeraSci). Now, as far as I understand it, these 2 companies aren't focused solely on cognition. They seem to be enabling remote clinical trials while also offering cognition tests.

What type of "threat" do these types of companies represent? I mean, if a sponsor goes to one of these companies looking for the "whole package", is it fair to assume that they'll tell the sponsor "Oh, we can do a lot of stuff for you, cognition testing included"?

I'm sure that if a sponsor wants the best technology for its trial, they'll go with Cambridge Cognition, but what if cognition isn't the main focus for them? Won't these "we do it all" companies benefit from already being involved in the clinical trials while Cambridge Cognition is trying to get the sponsors to notice it? Is it fair to assume that, if cognition is just a secondary endpoint, a sponsor will go with the integrated solution?

Cheers

[40 fathoms] 05/3/2022 00:52

I found this which Is really interesting.



They mention using Cambridge Cognitions data collection platform (eCOA) in a decentralised trial for Chronic Vomiting Syndrome. It appears this was a trial that did not measure cognition and is not obviously CNS related.

They also seem pretty happy with the process and results.

"Today, the learnings from this trial are helping to drive other remote studies, proving that thinking about rare diseases in a non-traditional manner can impact medicine on a much larger scale. CVS may only occur in a small percentage of the population, but many other patients around the world can benefit from decentralized, technology-based clinical trials and treatments"

The field of decentralised clinical trials and studies is wide open and although neurological conditions are amongst the easiest to transition to digital and decentralised the whole industry is moving in that direction. I guess if you are large Pharma and have a choice between an untested start up or product or a COG product that has been validated and tested in RW conditions, although perhaps not in your speciality area, you are probably going to go with the lower risk option.

[pauliewonder] 18/2/2022 12:32

Interesting podcast on Vox: hxxps://www.voxmarkets.co.uk/articles/vadim-alexandre-is-omega-diagnostics-good-value-here--f879852/

Discussed ODX but COG is mentioned as a very good holding to have and that the market they operate in is growing at 20% per annum.

Been looking to buy into COG and finally taken the plunge this morning.